Intellia Therapeutics Stock Sees 67% Decline Amid Regulatory Setback and Mixed Earnings

Intellia Therapeutics' shares have declined 67.3% in a month due to regulatory setbacks and mixed Q3 earnings. The company's lead candidate, nex-z, faces a clinical hold after liver enzyme elevations were observed in some patients. Intellia is working with investigators and regulators to address the issue and develop risk-mitigation strategies. The company's other in vivo candidate, lonvo-z, is being evaluated in a phase III study for treating hereditary angioedema.